Correspondence to: M Kawahara pnmarn cancer >-as taken as the day of histological or cytological documentation of redevelopment of cancer. The appearance of SCLC more than 2 y-ears after the initiation of therapy A-as defined as relapse.
MATERIALS AND METHODS Patients
From Januarv 1978 to December 1992. 980 consecutix-e patients with histologically confirmed. previously untreated SCLC were treated at the National Kinki Central Hospital and Osaka Prefectural Habikino Hospital A ith combination chemotherapy with or w-ithout chest radiotherapy.
Definitions
The upper aerodigestive tract includes the epithelial regions of the head and neck. lunc and oesophagus. Smoking-related cancers include cancers of the lung. larvmx. oral cavity including phanrnx.
oesophagus. pancreas. bladder. kidney. stomach and uterine cernix (Blum. 1993 Correspondence to: M Kawahara pnmarn cancer >-as taken as the day of histological or cytological documentation of redevelopment of cancer. The appearance of SCLC more than 2 y-ears after the initiation of therapy A-as defined as relapse.
Statistical analysis
For estimation of the expected x-alues of second cancer desvelopment. the period of risk began 2 years after initiation of treatment for SCLC and ended with the date of death. date of last follow -up or date of diagnosis of a second cancer. w-hichever occurred first.
Age. sex. and period-specific rates for cancer incidence x-ithin the period 196-3-92 were applied to the appropriate person-years of obsernation (Osaka Prefectural Department of Environment and Public Health. 1993: Osaka Prefectural Department of Health. 1995). The cancer incidence data for 1992 A-ere applied to the person-years from 1992 to 1995. Statistical methods for risk estimation Nvere based on the assumption that the obserned number of second cancers follow-ed a Poisson distribution (Boice et al. 1991 ) . To calculate excess risks per 10 000 patients per y ear in subgroups w-ith sianificant relatix-e risks. the expected number of cases w-as subtracted from the number observed. The difference A as divided by person-years of observation. then multiplied by IO-. The risk of a SPT with a specific exposure (e.g. smoking and treatment) x-as estimated by comparing the patients w ithout the specific exposure. using Poisson regression methods (SAS Institute. 1989) adjusting for sex. age (> 65 vs < 65 nears old). performance status (PS) (0-1 Xs 2-4). etoposide. radiotherapy and cumulatiVe smoking amount before diacnosis of SCLC (> 45 pack-y ear vs < 45 pack-years ).
RESULTS
Of the 980 patients of SCLC treated in the two hospitals. 70 (7%5 x-ere alive and free of cancer at least 2 vears after the initiation of treatment. The median survival time of these 70 patients >-as 9.0 years from initiation of treatment for SCLC. Five-and 10-vear survival rates A-ere 83=/e and 43% respectixely. Ten patients wxere Of the 70 patients. nine relapsed with SCLC. These relapses occurred 2.0-8.5 years after the initiation of SCLC. Twentx -fixve patients have died: five from recurrent SCLC. 11 from a SPT. The other causes of deaths unrelated to cancer were pulmonary disease (n = 3). cardiac disease (n = 2). cerebrovascular disease (n = 1).
neurological disease (dementia after whole brain irradiation for SCLC) (n = 1) and unknown (n=). (63%) . from relatives for 20 (29%) and from the patients' medical records for five (77c). There has been no SPT among the fixve nexver smokers. After initiating therapy for SCLC. 33 patients (49%/c) continued to smoke and 31 patients (48%7c) stopped smoking (Table 3) . Of the patients xho continued to smoke. 11 (33%7c) dex eloped a SPT. Of the 31 patients x ho stopped smoking after therapy. only three (10%c) had a subsequent SPT (cancer of the stomach. oesophagus and gallbladder respectixely. see Table 1 ). Among those wxho continued to smoke. the risk for a SPIT was significantly increased (5.4 times: 95%7c CI 2.7-9.7). relatixe to the aeneral population. In contrast. those wxho stopped smoking showxed only a 1.6-fold increase (95%7c CI 0.3-4.6). which wxas not significantlx different from the lexel in the general population. The relative risk for non-SCLC was sianificantlv increased 12.8-fold (95c/c CI 3.4-32.8) in continuing smokers. No second non-SCLCs have been found amona those x ho stopped smoking.
We assessed the relationship betxxeen continued smokin2 habits and the risk of a SPT. adjusted for sex. PS. age. etoposide treatment. radiotherapy and cumulatixe smoking history. The results are showxn in Table 4 . The 33 patients who continued to smoke had a significantly increased risk of a SPF (4.3. 95%7c CI 1.1-15.9. P=0.03). The other factors such as sex. PS. age. cumulative smokine amount. use of the anticancer drug etoposide or radiation had no effect on the dex elopment of a SPI. We assessed the interaction between smoking habits and radiotherapy on the risk of a SPT. Relative to the risk of SPT in patients without previous radiotherapy wxho stopped smokingy. the risk is 0.92 in patients without radiotherapy wxho continued smoking. 0.37 in patients with radiotherapy who stopped smoking. and 2.33 in patients with radiotherapy who continued smoking. The risk of current smoking in patients with previous radiotherapy is 6.30 relatixve to those xith radiotherapy wxho stopped smoking. although this interaction is not statistically significant (P = 0.24 
